Saturday☕️

Trending:
- Novo Nordisk Earnings
- AWS EU Sovereign Cloud
Markets:
- Yesterday’s U.S. stock market:

- Yesterday’s commodity market:

- Yesterday’s crypto market:

Novo Nordisk Earnings:
- Novo Nordisk, the pharmaceutical giant from Denmark, has witnessed its revenue surge by 38% in the last quarter, fueled largely by the skyrocketing sales of its weight loss medication Wegovy. The company, also known for Ozempic, a diabetes treatment, has seen both medications experience a dramatic uptick in demand within the US market.
- This growth has catapulted Novo Nordisk to the position of the most valuable company in Europe. Their latest earnings report for Q3 highlighted not just the revenue boost but also a significant 47% leap in operating profits. Wegovy's sales have seen an astounding 734% jump, while Ozempic has increased by 46%. The CEO has acknowledged that the current demand is outstripping the supply of these drugs.
AWS EU Sovereign Cloud:
- Amazon Web Services (AWS) is launching a new cloud region specifically for European customers who need to keep their data within the EU and meet strict regulatory requirements. This AWS European Sovereign Cloud will be a separate and secure infrastructure, managed entirely by EU-based personnel. It's designed to cater to the public sector and industries with high compliance demands, ensuring operational control remains within the EU for data residency and autonomy.
- The first of these sovereign cloud regions will be set up in Germany, providing the same level of service and security that AWS is known for. It's built with independent operation in mind, including separate billing and usage systems confined to the EU. The cloud will also have multiple availability zones for increased reliability and will maintain strict data encryption practices.
- This initiative is part of AWS's continued investment in Europe, which includes job creation and economic contributions across the EU. AWS is collaborating closely with European regulators and cybersecurity authorities, such as Germany's Federal Office for Information Security, to align with local standards and contribute to Europe's digital sovereignty and security.
Statistic:
- Top 50 pharmaceutical companies by market cap:
- 🇺🇸 Eli Lilly: $539.02B
- 🇩🇰 Novo Nordisk: $438.80B
- 🇺🇸 Johnson & Johnson: $364.31B
- 🇺🇸 Merck: $262.32B
- 🇺🇸 AbbVie: $249.61B
- 🇨🇭 Roche: $212.65B
- 🇬🇧 AstraZeneca: $198.26B
- 🇨🇭 Novartis: $190.66B
- 🇺🇸 Pfizer: $176.49B
- 🇺🇸 Amgen: $144.42B
- 🇫🇷 Sanofi: $114.85B
- 🇺🇸 Bristol-Myers Squibb: $107.47B
- 🇺🇸 Gilead Sciences: $101.66B
- 🇺🇸 Vertex Pharmaceuticals: $97.09B
- 🇺🇸 CVS Health: $90.40B
- 🇺🇸 Regeneron Pharmaceuticals: $88.99B
- 🇦🇺 CSL: $76.75B
- 🇺🇸 Zoetis: $74.67B
- 🇬🇧 GlaxoSmithKline: $71.35B
- 🇩🇪 Merck KGaA: $68.26B
- 🇯🇵 Daiichi Sankyō: $51.91B
- 🇯🇵 Chugai Pharmaceutical: $50.79B
- 🇩🇪 Bayer: $44.43B
- 🇯🇵 Takeda Pharmaceutical: $43.96B
- 🇨🇳 Jiangsu Hengrui Medicine: $41.51B
- 🇺🇸 Seagen: $40.56B
- 🇺🇸 Biogen: $36.13B
- 🇨🇳 WuXi AppTec: $34.68B
- 🇮🇳 Sun Pharmaceutical: $32.93B
- 🇳🇱 Argenx: $29.53B
- 🇺🇸 Moderna: $29.50B
- 🇨🇭 Lonza: $27.19B
- 🇨🇳 WuXi Biologics: $26.70B
- 🇮🇪 Horizon Therapeutics: $26.63B
- 🇺🇸 West Pharmaceutical: $24.78B
- 🇩🇪 BioNTech: $22.96B
- 🇯🇵 Astellas Pharma: $22.25B
- 🇮🇪 ICON plc: $21.24B
- 🇺🇸 Alnylam Pharmaceuticals: $21.00B
- 🇨🇳 BeiGene: $19.88B
- 🇯🇵 Otsuka Holdings: $19.65B
- 🇺🇸 Walgreens Boots Alliance: $19.10B
- 🇩🇰 Genmab: $19.03B
- 🇺🇸 LabCorp: $17.84B
- 🇺🇸 Baxter: $17.22B
- 🇬🇧 Royalty Pharma: $16.82B
- 🇰🇷 Celltrion: $16.18B
- 🇯🇵 Eisai: $15.58B
- 🇺🇸 BioMarin Pharmaceutical: $14.98B
- 🇯🇵 Shionogi: $13.98B
Article Links:


Thanks for reading!
TIME IS MONEY: Your Free Daily Scoop of Markets📈, Business💼, Tech📲🚀, and Global 🌎 News.
The news you need, the time you want.

Support/Suggestions Emails:
timeismoney@timeismon.news